$0.51 Earnings Per Share Expected for LivaNova PLC (NASDAQ:LIVN) This Quarter

Brokerages expect LivaNova PLC (NASDAQ:LIVNGet Rating) to announce earnings per share of $0.51 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for LivaNova’s earnings. LivaNova reported earnings of $0.52 per share in the same quarter last year, which would suggest a negative year over year growth rate of 1.9%. The firm is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that LivaNova will report full year earnings of $2.59 per share for the current year, with EPS estimates ranging from $2.57 to $2.61. For the next financial year, analysts anticipate that the business will post earnings of $3.00 per share, with EPS estimates ranging from $2.88 to $3.12. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that cover LivaNova.

LivaNova (NASDAQ:LIVNGet Rating) last released its quarterly earnings results on Wednesday, May 4th. The company reported $0.48 EPS for the quarter, hitting the consensus estimate of $0.48. The firm had revenue of $240.20 million for the quarter, compared to analyst estimates of $231.57 million. LivaNova had a positive return on equity of 9.57% and a negative net margin of 9.69%. LivaNova’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.35 EPS.

Several equities analysts recently commented on the company. Zacks Investment Research lowered LivaNova from a “hold” rating to a “sell” rating in a research report on Tuesday, May 10th. Piper Sandler cut their target price on LivaNova from $104.00 to $99.00 in a research report on Thursday, May 5th. StockNews.com assumed coverage on LivaNova in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. Needham & Company LLC cut their target price on LivaNova from $120.00 to $106.00 and set a “buy” rating on the stock in a research report on Thursday, February 24th. Finally, Wolfe Research assumed coverage on LivaNova in a research report on Tuesday, April 5th. They issued an “outperform” rating and a $95.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. According to MarketBeat, LivaNova has a consensus rating of “Buy” and a consensus price target of $100.71.

In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 2nd. The stock was sold at an average price of $80.00, for a total transaction of $80,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Damien Mcdonald sold 2,784 shares of the company’s stock in a transaction on Tuesday, March 29th. The stock was sold at an average price of $81.50, for a total value of $226,896.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,784 shares of company stock worth $390,316. Corporate insiders own 0.37% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. grew its stake in shares of LivaNova by 1.5% in the fourth quarter. BlackRock Inc. now owns 6,349,305 shares of the company’s stock worth $555,120,000 after purchasing an additional 92,200 shares in the last quarter. Primecap Management Co. CA grew its stake in shares of LivaNova by 2.5% in the first quarter. Primecap Management Co. CA now owns 4,526,965 shares of the company’s stock worth $370,442,000 after purchasing an additional 111,520 shares in the last quarter. Harris Associates L P grew its stake in shares of LivaNova by 1.3% in the first quarter. Harris Associates L P now owns 3,872,581 shares of the company’s stock worth $316,893,000 after purchasing an additional 49,315 shares in the last quarter. State Street Corp grew its stake in shares of LivaNova by 1.4% in the fourth quarter. State Street Corp now owns 2,418,004 shares of the company’s stock worth $211,406,000 after purchasing an additional 34,304 shares in the last quarter. Finally, Eminence Capital LP grew its stake in shares of LivaNova by 6.7% in the first quarter. Eminence Capital LP now owns 1,948,147 shares of the company’s stock worth $159,417,000 after purchasing an additional 122,470 shares in the last quarter. Hedge funds and other institutional investors own 97.34% of the company’s stock.

LivaNova stock opened at $67.53 on Friday. The stock’s 50 day moving average price is $75.41 and its 200 day moving average price is $78.42. The firm has a market capitalization of $3.61 billion, a PE ratio of -33.93 and a beta of 0.91. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.26 and a current ratio of 2.63. LivaNova has a one year low of $58.18 and a one year high of $93.89.

About LivaNova (Get Rating)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Further Reading

Get a free copy of the Zacks research report on LivaNova (LIVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.